Study finds behavior matters far more to lifetime exposure to cancer-causing radiation than previously believed

by Allie Miller,University of CalgaryResidential radon exposure periods modified by radon awareness behavior and test decision-making that can differ by age, sex/gender or parental status. Credi

Updated on: January 23,2024 10

Study finds behavior matters far more to lifetime exposure to cancer-causing radiation than previously believed

by Allie Miller,University of CalgaryResidential radon exposure periods modified by radon awareness behavior and test decision-making that can differ by age, sex/gender or parental status. Credi

Updated on:January 23,2024 10

Race and geography linked to different risks of breast cancer treatment delays

byWileyCredit: Unsplash/CC0 Public DomainFor patients with cancer, lengthy delays in treatment can decrease their chances of survival. In an analysis of 2004–2017 information on patients with br

Updated on: January 23,2024 13

Race and geography linked to different risks of breast cancer treatment delays

byWileyCredit: Unsplash/CC0 Public DomainFor patients with cancer, lengthy delays in treatment can decrease their chances of survival. In an analysis of 2004–2017 information on patients with br

Updated on:January 23,2024 13

Cancer patients can quit smoking through lengthened medication time, counseling support

by Northwestern UniversityCredit: CC0 Public DomainQuitting smoking can significantly improve the effectiveness of cancer treatment, according to theU.S. Surgeon General,yet almost ha

Updated on: March 09,2024 10

Cancer patients can quit smoking through lengthened medication time, counseling support

by Northwestern UniversityCredit: CC0 Public DomainQuitting smoking can significantly improve the effectiveness of cancer treatment, according to theU.S. Surgeon General,yet almost ha

Updated on:March 09,2024 10

Novel FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

by Vall d'Hebron Institute of OncologyIntermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithel

Updated on: January 11,2024 10

Novel FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

by Vall d'Hebron Institute of OncologyIntermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithel

Updated on:January 11,2024 10

Study validates first-ever predictive AI biomarker of androgen deprivation therapy benefit in prostate cancer

by University Hospitals Cleveland Medical CenterProstate cancer cells. Credit: NIH Image GalleryData from a new study published inNEJM Evidenceshows promise for personalized use of sh

Updated on: February 20,2024 14

Study validates first-ever predictive AI biomarker of androgen deprivation therapy benefit in prostate cancer

by University Hospitals Cleveland Medical CenterProstate cancer cells. Credit: NIH Image GalleryData from a new study published inNEJM Evidenceshows promise for personalized use of sh

Updated on:February 20,2024 14

Study: More paid sick leave results in more cancer screenings

by Tulane UniversityCredit: Unsplash/CC0 Public DomainFor most Americans, the two major obstacles to proper medical care are time and money. And while insurance can sometimes reduce health care c

Updated on: February 18,2024 14

Study: More paid sick leave results in more cancer screenings

by Tulane UniversityCredit: Unsplash/CC0 Public DomainFor most Americans, the two major obstacles to proper medical care are time and money. And while insurance can sometimes reduce health care c

Updated on:February 18,2024 14

AI in personalized cancer medicine: New therapies require flexible and safe approval conditions

by Viktoria Bosak,Dresden University of TechnologyA perspective on the US and EU regulatory system readiness for AI-enabled personalized drug and cell-based therapies in precision oncology. The

Updated on: March 05,2024 11

AI in personalized cancer medicine: New therapies require flexible and safe approval conditions

by Viktoria Bosak,Dresden University of TechnologyA perspective on the US and EU regulatory system readiness for AI-enabled personalized drug and cell-based therapies in precision oncology. The

Updated on:March 05,2024 11

ASH: A+AVD beats ABVD for advanced Hodgkin's lymphoma

(HealthDay)—For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastin

Updated on: March 30,2024 14

ASH: A+AVD beats ABVD for advanced Hodgkin's lymphoma

(HealthDay)—For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastin

Updated on:March 30,2024 14

Detecting breast cancer earlier with 3D X-rays

by Werner Siefer,ETH ZurichComparison of conventional computed tomography with the new GI-CT images. The increased image quality of the GI-CT is particularly evident for small features (indicate

Updated on: February 23,2024 20

Detecting breast cancer earlier with 3D X-rays

by Werner Siefer,ETH ZurichComparison of conventional computed tomography with the new GI-CT images. The increased image quality of the GI-CT is particularly evident for small features (indicate

Updated on:February 23,2024 20

Drug-pricing program improves prostate cancer treatment adherence, finds study

by Nicole Fawcett,University of MichiganCredit: Unsplash/CC0 Public DomainProstate cancer patients receiving care at hospitals that are part of a special drug-pricing program were more likely to

Updated on: March 30,2024 0

Drug-pricing program improves prostate cancer treatment adherence, finds study

by Nicole Fawcett,University of MichiganCredit: Unsplash/CC0 Public DomainProstate cancer patients receiving care at hospitals that are part of a special drug-pricing program were more likely to

Updated on:March 30,2024 0

Predicting immunotherapy response and guiding combination therapy with MOTIF

byScience China PressWorkflow of MOTIF and three main application including cellular function analysis, immunotherapy response prediction and combinational therapy guidance. Credit: Science Chin

Updated on: March 30,2024 0

Predicting immunotherapy response and guiding combination therapy with MOTIF

byScience China PressWorkflow of MOTIF and three main application including cellular function analysis, immunotherapy response prediction and combinational therapy guidance. Credit: Science Chin

Updated on:March 30,2024 0

Researcher leads first in-human multiple myeloma study with over 90% response rate

by Indiana University School of MedicineMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Indiana University Melvin and Bren

Updated on: January 30,2024 12

Researcher leads first in-human multiple myeloma study with over 90% response rate

by Indiana University School of MedicineMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Indiana University Melvin and Bren

Updated on:January 30,2024 12